FY2024 EPS Estimates for AC Immune Lifted by Leerink Partnrs

AC Immune SA (NASDAQ:ACIU) – Leerink Partnrs raised their FY2024 earnings per share (EPS) estimates for shares of AC Immune in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($0.57) for the year, up from their prior forecast of ($0.60). The consensus estimate for AC Immune’s current full-year earnings is ($0.63) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($0.55) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of AC Immune in a report on Friday, November 15th.

AC Immune Price Performance

Shares of AC Immune stock opened at $2.70 on Friday. AC Immune has a 1-year low of $2.25 and a 1-year high of $4.98. The stock has a market cap of $267.14 million, a P/E ratio of -5.87 and a beta of 1.29. The stock’s 50 day simple moving average is $2.89 and its 200-day simple moving average is $3.19.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ACIU. Cubist Systematic Strategies LLC purchased a new stake in AC Immune in the 2nd quarter valued at approximately $218,000. China Universal Asset Management Co. Ltd. raised its stake in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in AC Immune by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after purchasing an additional 3,499 shares in the last quarter. 51.36% of the stock is owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.